ResearcherUniversity of Rome Tor VergataNo recent work listed

Mario Roselli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2431-6689; OpenAlex author ID A5072842070. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2016: 1 paper

Papers 1

Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Last author DOI 10.3233/cbm-160645 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Vincenzo Formica · 1 shared paper, 2016 · strength 0.05
- Paper Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. DOI 10.3233/cbm-160645 ↗
Vittore Cereda · 1 shared paper, 2016 · strength 0.05
- Paper Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. DOI 10.3233/cbm-160645 ↗
Antonio Dello Russo · 1 shared paper, 2016 · strength 0.05
- Paper Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. DOI 10.3233/cbm-160645 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.